Capricor Therapeutics shares surged 77% on Friday after the company said the U.S. health regulator is willing to review new data on its experimental Duchenne muscular dystrophy drug.
The stock had crashed last month after an FDA advisory panel voted nine-to-three against the effectiveness data of the drug, deramiocel.